## **Introducing Dimension Bio**

### _A New Name for a Bolder Future_

Five years ago, Dimension Inx embarked on a bold idea: **What if we could unite biology and engineering—to reimagine how biomaterials could truly change the way we treat patients?**

From our earliest pitch decks, we imagined therapies that could **restore or even replace lost organ function**—life-changing solutions for patients facing disease, trauma, or aging.

Early R&D confirmed the promise. Our biomaterial scaffolds uniquely demonstrated rapid vascularization, resistance to foreign body response, and a natural affinity for cells. It was a breakthrough, but also a signal: we could go further.

By 2022, what began as exploration became intentional. Our data strengthened. The platform evolved and matured into BioNidum™, our bioinspired delivery system that transforms cells into implantable, tissue-like therapies, i.e., tissue therapeutics. We explored ovarian cells to treat infertility and quickly advanced to islet cells for diabetes. This work revealed the potential for **first-in-class** impact in areas of urgent medical need. With insight from our board, advisors, and partners, we turned our focus to liver disease—a field in desperate need of innovation.

Backed by a strong foundation—an FDA-cleared biomaterial and a fully established GMP manufacturing process—we moved fast. Within a year, we had compelling preclinical data and a clear path to the clinic with our **tissue therapeutic for liver failure**.

Now, we’re doubling down on our founding vision: **to reimagine what’s possible in regenerative medicine.**

That vision deserves a name that reflects where we’re going.

**Dimension Bio represents not just what we’ve built—but everything that lies ahead. The platform, the passion, the purpose—they remain the same. But the scale? It’s bigger than ever.**

We’re just getting started—and we can’t wait to show you what’s next.